CVS Health Corporation
NYSE:CVSMedical - Healthcare Plans
-$0.59 today
- Market cap
- $104.08B
- Beta
- 0.62
- P/E (TTM)
- 42.8
- EPS (TTM)
- $2.30
- Dividend yield
- 2.70%
Volume 17.19M
Average 8.19M
CVS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
CVS Health CorporationNYSE: CVS
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $3B rose 193.3% year over year, ahead of the +35.6% change in trailing-twelve-month net income. Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at -26.4% a year.
Context
- Net income amounted to 0.4% of revenue in FY2025, down 0.8 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 17 analysts of $10.42B (+503.2%) for the fiscal year ending Dec 2026, a step up from the -62.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $3B+1.3% QoQ
- Last fiscal yearDec 2025
- $1.73B-62.3% YoY
- LTMJun 2026
- $6.1B+35.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 1.73B USD
- Year-over-year change
- -62.3%
- 4-year CAGR
- -31.8%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.73B | -62.3% |
| FY2024 | 2024-12-31 | 4.59B | -45.2% |
| FY2023 | 2023-12-31 | 8.37B | +93.4% |
| FY2022 | 2022-12-31 | 4.33B | -45.8% |
| FY2021 | 2021-12-31 | 7.99B | — |
Net Income vs competitors
How CVS compares with its peers on the latest reported figures
- CVS's LTM Jun 2026 net income of $6.1B is the 3rd largest of the 9 companies compared; the peer median is $896.47M.
- Its year-over-year change of +35.6% is the 3rd highest of 9, against a peer median of -5.8%.
- Net income amounts to 1.5% of revenue for CVS, versus a peer median of 2.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $16.67B | -8.1% | -14.0% | 3.7% | |
| LTM Sep 2026 | $6.71B | +2.4% | -2.5% | 2.3% | |
| LTM Jun 2026 | $6.1B | +35.6% | -26.4% | 1.5% | |
| LTM Jun 2026 | $5.11B | -350.3% | — | 2.6% | |
| LTM Sep 2026 | $5.1B | -7.7% | -2.0% | 2.5% | |
| LTM Sep 2026 | $1.24B | -3.9% | -24.6% | 0.8% | |
| LTM Jun 2026 | $550.93M | +443.4% | -10.1% | 3.6% | |
| LTM Sep 2026 | $48M | -105.4% | -15.8% | 0.1% | |
| LTM Mar 2026 | $19.79M | +121.8% | -83.1% | 0.5% | |
| Peer median (excluding CVS) | $896.47M | -5.8% | -14.0% | 2.4% | |
Competitors are the stored peer set for CVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.99B | 4.33B | 8.37B | 4.59B | 1.73B |
| Depreciation & Amortization | 4.49B | 4.22B | 4.37B | 4.6B | 4.61B |
| Deferred Income Tax | (402M) | (2.03B) | (676M) | (572M) | 102M |
| Stock-Based Compensation | 484M | 447M | 588M | 540M | 535M |
| Change in Working Capital | 3.86B | 6.82B | 15M | 109M | (1.47B) |
| Accounts Receivables | (2.7B) | (2.97B) | (6.26B) | (1.3B) | (3.5B) |
| Inventory | 735M | (1.44B) | 1.23B | (102M) | (1.27B) |
| Accounts Payables | 2.9B | 4.26B | 3.62B | 2.34B | 3.86B |
| Other Working Capital | 2.93B | 6.96B | 1.42B | (823M) | (564M) |
| Other Non-Cash Items | 1.85B | 2.39B | 765M | (153M) | 5.14B |
| Operating Cash Flow | 18.27B | 16.18B | 13.43B | 9.11B | 10.64B |
| Capital Expenditures | (2.52B) | (2.73B) | (3.03B) | (2.78B) | (2.83B) |
| Acquisitions (Net) | (146M) | (1.39B) | (16.61B) | (95M) | (436M) |
| Purchases of Investments | (9.96B) | (7.75B) | (9.04B) | (15.19B) | (15.01B) |
| Sales of Investments | 7.25B | 6.73B | 7.73B | 10.35B | 12.38B |
| Other Investing Activities | 122M | 85M | 68M | 101M | 26M |
| Investing Cash Flow | (5.26B) | (5.05B) | (20.89B) | (7.61B) | (5.87B) |
| Debt Repayment | (9.27B) | (4.21B) | 7.93B | 5.06B | (3.9B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 394M |
| Common Stock Repurchased | 0 | (3.5B) | (2.01B) | (3.02B) | 0 |
| Dividends Paid | (2.63B) | (2.91B) | (3.13B) | (3.37B) | (3.4B) |
| Other Financing Activities | 536M | 102M | (105M) | 202M | 1.96B |
| Financing Cash Flow | (11.36B) | (10.52B) | 2.68B | (1.14B) | (4.94B) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.65B | 614M | (4.78B) | 359M | (172M) |
| Free Cash Flow | 15.75B | 13.45B | 10.4B | 6.33B | 7.81B |
CVS Health Corporation
NYSE:CVS
Intrinsic Alpha fair value
Locked
Current Price
$81.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.